Cancers that appear morphologically similar often have dramatically different clinical
features, respond variably to therapy and have a range of outcomes. Compelling evidence …

Abstract Background Mesenchymal stem cells (MSCs) therapy is a novel treatment strategy
for cancer and a wide range of diseases with an excessive immune response such as …

Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32
recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH …

Pancreatic ductal adenocarcinoma (PDAC) remains a lethal disease with a 5-year survival
rate of 4%. A key hallmark of PDAC is extensive stromal involvement, which makes …

Pancreatic cancer remains one of the most lethal of malignancies and a major health
burden. We performed whole-genome sequencing and copy number variation (CNV) …

Patients with high-grade serous ovarian cancer (HGSC) have experienced little
improvement in overall survival, and standard treatment has not advanced beyond platinum …

Pancreatic cancer is a major cause of cancer-associated mortality, with a dismal overall
prognosis that has remained virtually unchanged for many decades. Currently, prevention or …

Exosomes are membrane vesicles which offer potential as blood derived biomarkers for
malign tumors in clinical practice. Pancreatic cancer is counted among cancer diseases with …

Despite the recent advances in chemotherapeutic treatments against cancer, some types of
highly aggressive and invasive cancer develop drug resistance against conventional …

Pancreatic cancer is molecularly diverse, with few effective therapies. Increased mutation
burden and defective DNA repair are associated with response to immune checkpoint …